Every Form 4 that Pfizer Inc. (PFE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PFE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFE filings page.
Pfizer Inc. Executive Vice President Lidia Fonseca reported receiving a grant of 82,284 stock appreciation rights on Pfizer common stock. These rights were acquired as a compensation award at a price of $0.0000 per right and are held as direct ownership.
According to the disclosure, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this grant, Fonseca held a total of 82,284 stock appreciation rights.
Pfizer Inc. Executive Vice President Michael McDermott received a grant of 151,576 Stock Appreciation Rights on March 3, 2026. These rights were acquired at a price of $0.00 per right as a form of equity-based compensation.
According to the disclosure, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this grant, McDermott directly holds 151,576 stock appreciation rights.
SAHNI PAYAL reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Payal Sahni received a grant of 108,268 stock appreciation rights. These derivative awards were granted at a price of $0.00 per right and are scheduled to be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, subject to vesting requirements.
de Germay Alexandre reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Alexandre de Germay received a grant of 194,883 stock appreciation rights on Pfizer common stock. These rights were awarded at no purchase price and are classified as a derivative security. According to the terms, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported a tax-related share disposition. On February 27, 2026, 655 shares of Pfizer common stock at $27.65 per share were withheld to cover tax obligations upon the vesting of restricted stock units, leaving her with 12,041 directly owned shares.
Pfizer Executive Vice President Payal Sahni reported transactions tied to stock appreciation rights. She exercised stock appreciation rights for 56,888 shares of common stock on February 25, 2026, at a stated exercise price of $33.82 per share, increasing her direct holdings.
To cover related tax obligations and exercise costs, 1,083 shares at $27.09 per share and 54,066 shares at $26.92 per share were withheld, classified as tax-withholding dispositions rather than open-market sales. After these transactions, she directly owned 27,667 Pfizer common shares and indirectly held 14,630 shares through a Rule 16b-3 plan.
Pfizer Inc. Executive Vice President Douglas M. Lankler settled stock-based compensation tied to stock appreciation rights on February 25, 2026. He exercised 122,907 stock appreciation rights, receiving the same number of Pfizer common shares at a reference price of $33.82 per share.
To cover related tax obligations and exercise price, 2,198 shares were withheld at $27.09 per share and 116,811 shares were withheld at $26.92 per share. Following these transactions, he held 163,177 shares of Pfizer common stock directly and 2,083 shares indirectly through a Rule 16b-3 plan.
Pfizer Inc. senior vice president and controller Jennifer B. D'Amico reported transactions tied to stock appreciation rights (SARs). On earn-out of these SARs, she acquired 17,558 shares of Pfizer common stock through an exercise or conversion at a reference price of $33.82 per share. In connection with the earn-out, 361 shares at $27.09 per share and 16,687 shares at $26.92 per share were withheld to cover tax obligations and the exercise price. After these tax-withholding dispositions, she directly owned 12,696 shares of Pfizer common stock. These moves reflect equity compensation settlement rather than open-market buying or selling.
Pfizer Inc. Chairman & CEO Albert Bourla reported multiple equity transactions involving stock appreciation rights and common shares. On February 25, 2026, he exercised 491,626 stock appreciation rights, which were settled in an equal number of Pfizer common shares at $33.82 per share.
According to the footnotes, this earn-out included dividend equivalents and used a 20-day average of Pfizer’s closing prices to determine settlement. To cover the exercise price and related tax obligations, 467,241 and 8,303 common shares were withheld at prices of $26.92 and $27.09 per share, categorized as tax-withholding dispositions rather than open-market sales.
After these transactions, Bourla directly owned 388,671 Pfizer common shares and indirectly held 6,003 additional shares through a Rule 16b-3 plan. The filing reflects an exercise and settlement of incentive awards with associated share withholding, rather than discretionary market trading.
Pfizer Inc executive Lidia Fonseca reported derivative and related share transactions tied to stock appreciation rights (SARs). On February 25, 2026, she exercised 56,888 SARs, receiving 56,888 shares of Pfizer common stock at an exercise price of $33.82 per share.
To cover taxes and exercise costs from this earn-out, 1,058 shares and 54,066 shares of common stock were withheld in tax-withholding dispositions at prices of $27.09 and $26.92 per share, respectively. After these transactions, her directly owned Pfizer common stock position was 46,455 shares, and the exercised SARs balance was reduced to zero. Footnotes specify these events arise from the earn-out and settlement terms of the SARs, which use a 20-day average closing price of Pfizer common stock.
Pfizer Inc. Executive Vice President Michael McDermott reported several equity-related transactions involving Pfizer common stock and stock appreciation rights. On February 25, 2026, he exercised 37,925 stock appreciation rights, which were settled in Pfizer common stock as part of an earn-out of these awards, including dividend equivalents. This exercise generated 37,925 common shares at a reference price of $33.82 per share, increasing his direct common stock holdings.
In connection with this earn-out and related restricted stock unit vesting, Pfizer withheld shares to cover tax obligations and exercise price. These withholding dispositions of common stock totaled 3,503 shares on February 26, 2026 at $27.10, plus 679 shares and 36,044 shares on February 25, 2026 at prices of $27.09 and $26.92 per share, respectively. After these transactions, McDermott directly held 74,308 Pfizer common shares, with the derivative stock appreciation rights position reported as fully settled.
Pfizer Inc. President of R&D Christoffel Boshoff reported equity award activity involving Pfizer common stock. On February 25, 2026, he acquired 13,383 shares at $0.0000 per share as the earn-out of performance share awards, including dividend equivalents, increasing his direct holdings to 168,212 shares.
On the same date, 6,833 shares were disposed of at $27.09 per share to cover tax obligations related to this earn-out, a tax-withholding disposition rather than an open-market sale, leaving 161,379 shares held directly. He also indirectly holds 709 shares through a Rule 16b-3 plan.
Pfizer Inc. President, R&D Christoffel Boshoff had 816 shares of common stock withheld on February 23, 2026 to cover tax obligations upon the vesting of restricted stock units, at a price of $27.06 per share. After this tax-withholding disposition, he directly holds 154,829 shares and indirectly holds 709 shares through a Rule 16b-3 plan.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported a tax-related share disposition. On the vesting of restricted stock units, 419 shares of common stock were withheld at $27.06 per share to satisfy tax obligations, leaving her with 12,186 directly held shares.
Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of derivative securities linked to Pfizer common stock. On 02/12/2026, he received 2,883 Phantom Stock Units SSP at $27.47 per unit under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
Each unit represents one phantom share of common stock and is settled in cash after his separation from service. Following this grant, Bourla beneficially owned 757,286 derivative units on a direct basis, providing additional deferred, cash-settled exposure to Pfizer’s share value rather than immediate stock ownership.
Pfizer Inc. executive Christoffel Boshoff reported a tax‑related share withholding tied to equity compensation. On January 30, 2026, 12,887 shares of Pfizer common stock were withheld at $26.44 per share to satisfy tax obligations upon vesting of restricted stock units, rather than being an open‑market sale. After this transaction, Boshoff beneficially owned 155,645 shares directly and 698 shares indirectly through a Rule 16b‑3 plan.
Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of 79 Phantom Stock Units SSP on January 14, 2026 at $25.58 per unit. Each unit represents one phantom share of Pfizer common stock and is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. After this transaction, Bourla held 743,136 phantom stock units. These units are settled in cash after his separation from service and can be moved into an alternative investment account at any time, so they function as deferred cash-based compensation rather than actual shares.
Pfizer Inc. director Mortimer J. Buckley reported a deferred compensation transaction involving phantom stock units tied to Pfizer common stock. On 12/31/2025, he acquired 1,506.024 phantom stock units, each representing one phantom share of common stock. These units reflect deferred director compensation, including dividend equivalents, and are designed to be settled in cash or Pfizer common stock at the director’s election after he retires from the Board of Directors. Following this transaction, Buckley beneficially owned a total of 15,078.063 phantom stock units, all held as a direct interest.
Pfizer Inc. director reports additional deferred compensation units
A Pfizer Inc. director reported acquiring 1,857.43 phantom stock units linked to Pfizer common stock on 12/31/2025. Each unit represents one phantom share of common stock. After this transaction, the director beneficially owns 149,314.146 derivative securities in the form of phantom stock units.
These units represent deferred director compensation, including dividend equivalents, that will be settled in either cash or Pfizer common stock at the director’s election after retirement from the Board of Directors.
Pfizer Inc director Shantanu Narayen reported acquiring 2,008.032 phantom stock units on Pfizer common stock as of 12/31/2025. Each unit represents one phantom share of common stock tied to deferred director compensation, including dividend equivalents.
These units are to be settled in cash or common stock at the director's election after retirement from the Board of Directors. Following this transaction, Narayen beneficially owned 183,164.359 derivative securities related to Pfizer common stock, recorded at a derivative security price of $24.9.
Pfizer Inc. director reports phantom stock unit grant tied to board compensation. On 12/31/2025, a reporting person serving as a Pfizer director acquired 1,556.225 phantom stock units linked to Pfizer common stock at a price of $24.9 per unit. These units represent deferred director compensation, including dividend equivalents, that can be settled in cash or Pfizer common stock at the director's election after retiring from the Board of Directors. Following this transaction, the director beneficially owned 74,697.055 derivative securities in the form of phantom stock units, held directly.
Pfizer Inc. director reports additional deferred compensation in phantom stock units. On 12/31/2025, director James C. Smith acquired 1,807.229 phantom stock units tied to Pfizer common stock at a derivative security price of $24.9. After this transaction, he beneficially owned 166,119.84 derivative securities directly.
Each phantom stock unit represents one phantom share of Pfizer common stock. These units reflect deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at the director’s election after he retires from the Board of Directors. The filing reports an acquisition of compensation-linked units rather than an open-market stock sale.
Pfizer Inc. director compensation update: A Pfizer Inc. (PFE) director reported receiving 1,506.024 phantom stock units on 12/31/2025 as part of deferred director compensation. Each unit represents one phantom share of common stock, with the units to be settled in cash or common stock at the director's election following retirement from the Board of Directors. After this transaction, the director beneficially owned 25,349.741 phantom stock units, held in direct form.
Pfizer Inc. Chairman and CEO Albert Bourla, who also serves as a director of Pfizer Inc. (PFE), reported a routine change in his deferred compensation holdings as of 12/31/2025. The filing shows the acquisition of 24 Phantom Stock Units SSP, a type of derivative security that tracks Pfizer common stock.
Each phantom unit represents one phantom share of Pfizer common stock and is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. These units are settled in cash after Bourla’s separation from service and may be moved into an alternative investment account at any time. Following this transaction, he beneficially owns 743,147 derivative securities related to these phantom stock units on a direct basis.
Pfizer Inc. Chairman and CEO Albert Bourla reported acquiring 23 phantom stock units linked to Pfizer common stock on 12/15/2025 under a deferred compensation plan.
Each unit represents one phantom share and is settled in cash after his separation from service. Following this transaction, Bourla beneficially owned 742,986 phantom stock units directly.
Pfizer Inc. Chairman and CEO Albert Bourla reported an insider equity transaction involving company-linked deferred compensation. On 11/28/2025, he acquired 23 Phantom Stock Units SSP, each representing one phantom share of Pfizer common stock at a reference price of $25.74 per unit. Following this transaction, he beneficially owns 743,115 phantom stock units.
The units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. They are settled in cash after Bourla’s separation from service and may be moved by him into an alternative investment account at any time. The filing is made by one reporting person in his roles as both director and Chairman & CEO.
Pfizer Inc. Chairman and CEO Albert Bourla reported acquiring 24 phantom stock units linked to Pfizer common stock on 11/14/2025 at $25.06 per unit under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is settled in cash after his separation from service, rather than in actual shares. The units may be transferred by him into an alternative investment account at any time. Following this transaction, he beneficially owned 743,548 derivative securities in the form of these phantom stock units, held in direct form.
Pfizer Inc. (PFE) insider activity: Chairman & CEO and Director Albert Bourla reported the acquisition of 24 phantom stock units on 10/31/2025 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
The filing lists a price of $24.65 for the derivative security and shows 731,108 derivative securities beneficially owned following the transaction, held as direct ownership. These phantom stock units represent the value of one share each and are settled in cash after the reporting person’s separation from service; they may be moved into an alternative investment account at any time.
Pfizer (PFE) reported an insider transaction by Chairman & CEO and Director Albert Bourla on 10/15/2025. The filing shows the acquisition of 25 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan at a price of $24.39 per unit. Following this transaction, Bourla’s derivative holdings total 731,111 phantom stock units, held directly. Each unit represents one phantom share of common stock and will be settled in cash after separation from service; units may be transferred into an alternative investment account at any time.
Pfizer Inc. (PFE) Chairman & CEO Albert Bourla reported acquiring 83 phantom stock units on 10/14/2025 at a derivative security price of $24.52. Following this transaction, he beneficially owns 731,058 derivative securities. Each unit represents one share of common stock and was acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, with settlement in cash after separation from service.
Cyrus Taraporevala, a Director of Pfizer Inc. (PFE), reported the acquisition of 1,471.743 phantom stock units on 09/30/2025. The filing shows these units represent deferred director compensation that may be settled in cash or common stock at the director's election following retirement. The units correspond to 1,471.743 underlying shares with an indicated per-share price of $25.48, and the report lists 23,444.776 shares beneficially owned by the reporting person after the transaction. The Form 4 was signed on 10/02/2025 by an attorney-in-fact, Shanice A. Reid.
Joseph J. Echevarria, a Director of Pfizer Inc. (PFE), reported an acquisition on 09/30/2025 of 1,815.149 phantom stock units that represent deferred director compensation. The filing shows these units were recorded as acquired with a per-share reference price of $25.48 and that 1,815.149 underlying common shares correspond to the units.
The form states these phantom units are deferred compensation that will be settled in cash or common stock at the director's election following the reporting person’s retirement from the Board. After the reported transaction the filing lists 144,989.542 common shares as beneficially owned. The form was signed by an attorney on behalf of Mr. Echevarria on 10/02/2025.